- Regulatory Status
- RUO
- Other Names
- Transmembrane Activator And CAML Interactor (TACI), TNF Receptor Superfamily Member 13B (TNFRSF13B), Tumor Necrosis Factor Receptor 13B, CD267, CVID2, IGAD2, CVID, RYZN, TNFRSF14B
-
Recombinant human TACI inhibits the proliferation of activated mouse B cells induced by recombinant mouse BAFF (Cat. No. 591202) in a dose-dependent manner. The ED50 for this effect is 3 - 12 ng/mL. -
Stability Testing for Recombinant Human TACI. Recombinant Human TACI was aliquoted in PBS, pH 7 at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaws) and compared to the control that was kept at 4⁰C (control). The samples were tested for their ability to inhibit the proliferation of activated B cells induced by recombinant mouse BAFF (Cat. No. 591202). The ED50 for this effect is 3 - 12 ng/mL.
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 779702 | 10 µg | $94.00 | |||
| 779704 | 25 µg | $206.00 | |||
| 779706 | 100 µg | $762.00 | |||
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) is a TNFR family member molecule and is part of the so-called BAFF system. This includes two ligands: B cell-activating factor of the TNF family (BAFF) and a proliferation-inducing ligand (APRIL), and three receptors: BAFFR (TNFRSF13C), TACI (TNFRSF13B), and B cell maturation Ag (BCMA or TNFRSF17). BAFF binds the three receptors, while APRIL binds TACI and BCMA. TACI is constitutively expressed on naïve B cells and is upregulated on activated B cells. TACI levels are severely reduced in newborn mice B cells compared with those of adult mice, and newborn B cells do not secrete immunoglobulins when they are stimulated with BAFF or APRIL. This reduced TACI expression might be responsible for the irresponsiveness of newborn B cells to T cell independent type II antigens such as bacterial capsular polysaccharides. The extracellular domain of TACI can be cleaved by ADAM10; this process results in a soluble TACI (sTACI) that assembles as an oligomeric complex that binds BAFF and APRIL and blocks B cell survival and activation. High levels of sTACI have been detected in different immunopathologies such as systemic lupus erythematosus (SLE), compartmentalized multiple sclerosis (MS), and non-Hodgkin lymphoma (NHL).
Product Details
- Source
- Human TACI, amino acid Ser2 - Thr166 (Accession # O14836) was expressed in 293E cells. The carboxy terminus contains linker -hFc- (Pro100 - Lys330).
- Molecular Mass
- The 404 amino acid recombinant protein has a predicted molecular mass of approximately 45.38 kD. The DTT-reduced and non-reduced protein migrate at approximately 55 kD and 100 kD respectively by SDS-PAGE. The predicted N-terminal amino acid is Ser.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 μm filtered protein solution is in PBS pH 7.2.
- Endotoxin Level
- Less than 1.0 EU per μg protein as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Recombinant human TACI inhibits the proliferation of activated mouse B cells induced by recombinant mouse BAFF (Cat. No. 591202) in a dose-dependent manner. The ED50 for this effect is 3 - 12 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Trimer
- Distribution
-
Peripheral B lymphocytes
- Function
- TACI triggers immunoglobulin class switching, IgG and IgA, by activating B cells through the adaptor MyD88. It also enhances the generation and maintenance of isotype-switched memory B lymphocytes and plasma cells, and increases the affinity of the produced antibody by the process of somatic hypermutation of the Ig gene. TACI drives plasma cell differentiation in LPS activated B cells. In addition, TACI is required in T-independent antibody production and in the regulation of B cell numbers. The interaction between B cells (expressing TACI) and DC (expressing BAFF) induces a rapid DC maturation which primes naive CD8+ T cells.
- Interaction
- B cells, myeloid cells, and monocyte-derived dendritic cells.
- Ligand/Receptor
- APRIL (TNFSFL13A, CD256) and BAFF (TNFSFL13B, CD257) are TACI ligands.
- Bioactivity
- Recombinant Human TACI inhibits the proliferation of activated mouse B cells induced by recombinant mouse BAFF.
- Cell Targets
- B cells, myeloid cells, and monocyte-derived dendritic cells.
- Cell Type
- B cells, Lymphocytes
- Biology Area
- Cell Biology, Immunology, Costimulatory Molecules
- Molecular Family
- CD Molecules, Soluble Receptors
- Antigen References
-
- Schneider P, et al. 1999. J. Exp. Med. 189:1747.
- Diaz-de-Durana Y, et al. 2006. Blood 107:594.
- Kanswal S, et al. 2008. J. Immunol. 181:976.
- Yang J, et al. 2009. PLOS One 4:e8494.
- Ozcan E, et al. 2009. J. Allergy Clin. Immunol. 123:1277.
- He B, et al. 2010. Nat. Immunol. 11:836.
- Garibyan L, et al. 2007 J. Clin. Invest. 117:1550.
- Hoffmann FS, et al. 2015 J. Immunol. 194:542.
- Shen X, et al. 2016 Adv. Clin. Exp. Med. 25:837.
- Gene ID
- 23495 View all products for this Gene ID
- UniProt
- View information about TACI on UniProt.org